The main office of represented Corporate Investor is situated in the Shanghai. The company was established in Asia in China.
The typical case for the fund is to invest in rounds with 3 participants. Despite the Qiaojing Capital, startups are often financed by Panda Capital, In Capital, Highlight Capital. The meaningful sponsors for the fund in investment in the same round are Gaorong Capital, Telescope, Shanghai Blossom Investment Management. In the next rounds fund is usually obtained by Yijing Capital, Xiamen Changrong Investment Management, StarVC.
The high activity for fund was in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year. The real fund results show that this Corporate Investor is 9 percentage points more often commits exit comparing to other companies.
This organization was formed by Kim Min, Zhu Haorong.
The fund has no exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 1 and less years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Dianwoda, iyiou.com, Innostic For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most successful fund investment fields, there are Supply Chain Management, Medical.
Related Funds
Funds with similar focus
Fund Name | Location |
B. Braun Medical | Bethlehem, Pennsylvania, United States |
Daji Renhe | Beijing, Beijing, China |
Evergreen Coast Capital | California, Menlo Park, United States |
Hanhui Touzi | China, Guangdong, Guangzhou |
Hanover Technology Investment Management | California, Menlo Park, United States |
Junlian Yikang | Beijing, China, Haidian |
Nichirin | Japan, Minato |
Techgate | - |
Techspring Partners | - |
True Partners Consulting | Chicago, Illinois, United States |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Yisheng Microna | $6M | 13 Mar 2024 | Wuxi Shi, Jiangsu, China | ||
Elite Technology | $15M | 05 Jan 2024 | Dalian Shi, Liaoning, China | ||
Hicicare | $15M | 07 Dec 2023 | Guangdong, Tianjin, China | ||
Jianxin Biotech | 20 Mar 2023 | Minhang, Shanghai, China | |||
Jinfang Pharmaceutical | $75M | 09 Mar 2023 | Shanghai, Shanghai, China | ||
Leto Laboratories | $15M | 16 Oct 2020 | China, Beijing | ||
$2M | 21 Aug 2018 | Shanghai, China | |||
Innostic | $38M | 30 Jan 2018 | Dongcheng District, Beijing, China | ||
Oranger | $10M | 24 Feb 2017 | Hexi, Tianjin, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Yisheng Microna | $6M | 13 Mar 2024 | Wuxi Shi, Jiangsu, China | ||
Elite Technology | $15M | 05 Jan 2024 | Dalian Shi, Liaoning, China | ||
Hicicare | $15M | 07 Dec 2023 | Guangdong, Tianjin, China | ||
Jianxin Biotech | 20 Mar 2023 | Minhang, Shanghai, China | |||
Jinfang Pharmaceutical | $75M | 09 Mar 2023 | Shanghai, Shanghai, China | ||
Leto Laboratories | $15M | 16 Oct 2020 | China, Beijing | ||
$2M | 21 Aug 2018 | Shanghai, China | |||
Innostic | $38M | 30 Jan 2018 | Dongcheng District, Beijing, China | ||
Oranger | $10M | 24 Feb 2017 | Hexi, Tianjin, China |